41717-26-4

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(2 4 6-Trimethylbenzyl)piperazine is used as an intermediate in the synthesis of pharmaceuticals for its ability to impart specific properties to the molecules, enhancing their efficacy and pharmacological activities.
Used in Agrochemical Synthesis:
In the agrochemical industry, 1-(2 4 6-Trimethylbenzyl)piperazine serves as an intermediate in the production of various agrochemicals, contributing to the development of effective and targeted solutions for agricultural applications.
Used in Organic Compound Synthesis:
1-(2 4 6-Trimethylbenzyl)piperazine is utilized as an important intermediate in the synthesis of a wide range of organic compounds, thanks to its unique structure and the properties conferred by the 2,4,6-trimethylbenzyl group.
Potential Pharmaceutical Uses:
Given the known pharmacological activities of piperazines, 1-(2 4 6-Trimethylbenzyl)piperazine may have potential uses in the development of new pharmaceuticals, leveraging its specific structural features for targeted therapeutic effects.

InChI:InChI=1/C14H22N2/c1-11-8-12(2)14(13(3)9-11)10-16-6-4-15-5-7-16/h8-9,15H,4-7,10H2,1-3H3

Upstream product

• 110-85-0 piperazine 
• 1585-16-6 2-chloromethyl-1,3,5-trimethylbenzene 

Downstream Products

• 109006-01-1 3-rifamycin SV 
• 123812-42-0 16,17,18,19-tetrahydro-3-rifamycin SV 
• 123812-43-1 16,17,18,19,28,29-hexahydro-3-rifamycin SV 
• 41717-09-3 N-(2,4,6-Trimethylbenzyl)-N-2-methyl-5,6-dihydro-pyran-3-carbonyl-piperazine-hydrochloride 
• 1218949-63-3 1-[3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl]-2-[4-(2,4,6-trimethylbenzyl)piperazin-1-yl]-ethanone 
• 1289155-16-3 (S)-2-((1-(benzylsulfonyl)pyrrolidin-3-yl)amino)-1-(4-(2,4,6-trimethylbenzyl)piperazin-1-yl)ethanone 
• 1289155-03-8 2-chloro-1-(4-(2,4,6-trimethylbenzyl)piperazin-1-yl)ethanone 
• 1353278-76-8 3-amino-1-[{4-(2,4,6-trimethylbenzyl)piperazin-1-yl}propanoyl]-6-N-(p-tolyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one 
• 1353278-78-0 C₁₇H₂₅ClN₂O 

Relevant academic research and scientific papers

Rational modifications, synthesis and biological evaluation of new potential antivirals for RSV designed to target the M2-1 protein

Respiratory syncytial virus (RSV) is the main cause of lower respiratory tract diseases in infants and young children, with potentially serious and fatal consequences associated with severe infections. Despite extensive research efforts invested in the identification of therapeutic measures, no vaccine is currently available, while treatment options are limited to ribavirin and palivizumab, which both present significant limitations. While clinical and pre-clinical candidates mainly target the viral fusion protein, the nucleocapsid protein or the viral polymerase, our focus has been the identification of new antiviral compounds targeting the viral M2-1 protein, thanks to the presence of a zinc-ejecting group in their chemical structure. Starting from an anti-RSV hit we had previously identified with an in silico structure-based approach, we have designed, synthesised and evaluated a new series of dithiocarbamate analogues, with which we have explored the antiviral activity of this scaffold. The findings presented in this work may provide the basis for the identification of a new antiviral lead to treat RSV infections.

Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors

Based on the literature-reported compensatory effect of PI3K on Abl inhibition and the improved preclinical effect of drug combination of Abl and PI3K inhibitors, a series of compounds bearing novel scaffold of (S)-3-aminopyrrolidine was identified as Abl and PI3K dual inhibitors through support vector machine screening tool, which were subsequently synthesized and tested. Most compounds demonstrated promising cytoxicity against a CML leukemia cell-line K562 and moderate inhibition against Abl and PI3K kinases. These compounds induced no apoptosis in K562 cell-line, suggesting that their cytotoxic activities are unlikely duo to other known anti-CML mechanisms. Molecular docking study further showed that the compound 5k could bind with both Abl and PI3K, but the weaker binding with Abl compared to Imatinib is consistent with its low kinase inhibitory rates. These plus literature-reported evidences suggest that the promising cytotoxic effect of our novel compounds might be due to the collective effect of Abl and PI3K inhibition.

INHIBITORS OF STEAROYL-COA DESATURASE

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.